Always taking RISK - do your own DD
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Antibe’s Chief Scientific Officer to Present at 5th World Congress on Hydrogen Sulfide in Biology and Medicine. The conference is being held at the Intercontinental Yorkville Hotel in Toronto, Canada from May 31st to June 3rd, 2018.
https://www.bioportfolio.com/news/article/3642175/Antibes-Chief-Scientific-Officer-to-Present-at-5th-World-Congress-on-Hydrogen.html
Would love your guy’s take on Antibe who has discovered a game changer medicine for NSAID.
MAY 24, 2018
Calgary Researchers Discover a Novel Approach to Treatment of Inflammatory Bowel Diseases (IBD) Using Hydrogen Sulfide Technology
https://finance.yahoo.com/news/calgary-researchers-discover-novel-approach-110000337.html
MAY 24, 2018
Calgary Researchers Discover a Novel Approach to Treatment of Inflammatory Bowel Diseases (IBD) Using Hydrogen Sulfide Technology
https://finance.yahoo.com/news/calgary-researchers-discover-novel-approach-110000337.html
MannKind Announces STAT Study Results Accepted for Presentation at American Diabetes Association’s 78th Scientific Sessions
WESTLAKE VILLAGE, Calif., March 13, 2018 (GLOBE NEWSWIRE) -- MannKind Corporation(Nasdaq:MNKD) focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension, today announced that research results from two analyses have been accepted for presentation at the American Diabetes Association’s 78th Scientific Sessions, June 22-26, 2018 in Orlando, Florida:
“Improved Postprandial Blood Glucose (PPBG) Excursions with Technosphere Inhaled Insulin Compared with Aspart in T1D Patients – STAT Study” will be an oral presentation
“Improved Time-in-Range (TIR) on Continuous Glucose Monitor (CGM)with Technosphere Inhaled Insulin (TI) Compared with Aspart in T1D Patients – STAT Study” will be presented during the scientific poster session
The STAT study (STudy comparing insulin Aspart versus Technosphere insulin in patients with type 1 diabetes on multiple daily injections) is the first MannKind study to include and prospectively evaluate the use of continuous glucose monitoring with Afrezza therapy. The dual primary endpoints were assessment of glucose time-in-range as well as post-prandial glucose excursions in the 1-4 hour post-meal period.
“We are very pleased with the opportunity to present the STAT Study results at the 78th Scientific Sessions of the American Diabetes Association”, stated Dr. Satish Garg (Barbara Davis Center for Diabetes, University of Colorado Denver), senior author and principal investigator of the collaborative multicenter randomized study.
“MannKind welcomes the opportunity to share the results of this collaborative clinical trial and looks forward to pursuing additional analyses to assess the clinical use of Afrezza therapy for mealtime glucose control,” stated David Kendall, MD, Chief Medical Officer of MannKind Corporation. “We believe that the STAT Study results will offer important insights into ways that individuals with diabetes can potentially improve their experience and outcomes by using mealtime inhaled insulin ’in the moment.‘ Our long-term goal is to establish inhaled human insulin as both a useful option and a potential treatment of choice for those individuals with diabetes requiring mealtime glucose control.”
http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-announces-stat-study-results-accepted-presentation
Organigram updates Investor Presentation
https://www.organigram.ca/assets/Investor-Deck/Organigram-InvestorsDeck-May-16noVideo-002.pdf
Did Scott finally go to jail?
Looks like float is locked ????????
I doubt people left LLY to join MNKD if they didn’t know Afrezza was going to be huge one day, don’t sleep on the moves being made by management. I don’t care about the last, I live in the future and the moment.
Product works, company is awesome, major product awareness campaign underway.
Long
I agree, Aftezza will soon be a household brand globally, major revenues, future is bright.
Don’t be left on the sidelines, good luck
Expecting a bull run thanks to Trump
Gotta love how they announced Neovasc Regains Compliance with Nasdaq Minimum Market Value Rule and then give us the BS numbers AH.
Company isn’t getting bought out bro, I worked there, it’s a legit company and profitable company. They simply got screwed over buying the Modern Video Film building and got stuck with them. Lot of the employees went from modern to .360 and are still there. It’s a great company to work for and they are making major moves into the next generation (4K) material and all. Major clients include Netflix, Amazon, Paramount, Sony Pictires and HULU, not including all the other remaining studios. It’s a top of the notch company. 1 of only 3 preferred vendors in Post Production for Netflix, that’s a big deal in the industry. Hope this helps.
Disclaimer: I have zero shares.
Hope this helps!
Good luck all!
Still here, don’t get this manipulation, let’s get back to .004 and eventual .01
Still dead and silent with these guys, wow. Someone please wake these guys up and see if there’s an update
This definitely has a chance to hit multi pennies with the right news, min .01 without news
True that, just saying that people who sell on the bid kill the MOMO, that’s all. Either way, ABCE is headed to .01, I’ll be patient, good luck ??????
ABCE best sub penny play ATM, definitely heading .01, people need to stop selling on bid and this will fly quick. ??????
I have a question. What will happen if the chapter 11 does go through, after all this is all due to couple of bad investments they made by purchasing the Modern Video Film facility and now they realized that it was a bad deal. From my understanding, all employees from Modern Video Film went to .360 Burbank location. Company still operates on 2 separate buildings is my understanding and has close to 500 employees and is profitable.
Thanks
Looks great:), will be buying more. What’s not to like about the news. Company is making deals for the long run and their patented technology will be global. I’m cool with today’s action! GLTU
You are so transparent with your posts, congratulations
Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Enters License Agreement with California Cannabis Beverage Maker
https://www.networknewswire.com/lexaria-bioscience-corp-cse-lxx-otcqx-lxrp-enters-license-agreement-with-california-cannabis-beverage-maker/
NEWS OUT
Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Enters License Agreement with California Cannabis Beverage Maker
https://www.networknewswire.com/lexaria-bioscience-corp-cse-lxx-otcqx-lxrp-enters-license-agreement-with-california-cannabis-beverage-maker/
LODE @.34
Itronics Announces: Positive Results From KAM-Thio Tests With Comstock Mining to Recover Silver, Gold While Neutralizing Cyanide
https://finance.yahoo.com/news/itronics-announces-positive-results-kam-114500561.html
LODE @.34
Itronics Announces: Positive Results From KAM-Thio Tests With Comstock Mining to Recover Silver, Gold While Neutralizing Cyanide
https://finance.yahoo.com/news/itronics-announces-positive-results-kam-114500561.html
Antibe Therapeutics Inc. ("Antibe" or the "Company”) (TSXV: ATE, OTCQB: ATBPF) is pleased to announce that it will be presenting at the upcoming Bloom Burton & Co. Healthcare Investor Conference being held on May 2 – 3, 2018 in Toronto, Canada.
Event: Seventh Annual Bloom Burton & Co. Healthcare Investor Conference
Location: Hall B, Lower Concourse Level, Sheraton Centre Toronto Hotel (Toronto, Canada)
Date: Wednesday, May 2nd, 2018
Time: 3:00 pm (ET)
Antibe’s CEO, Dan Legault, will deliver the Company’s presentation and will discuss recent business highlights and its growth strategy. Antibe will also be available for one-on-one investor meetings on both days of the conference.
About the Conference
Bloom Burton & Co. ("Bloom Burton”) is hosting its seventh annual Healthcare Investor Conference on May 2 and 3, 2018, at the Sheraton Centre Toronto Hotel, Toronto, Canada. Bloom Burton will host approximately 60 of Canada’s premier publicly traded and venture-backed private companies together with the most promising pre-venture companies in the healthcare industry. The event will attract Canadian, U.S. and International investors who are interested in the latest developments in Canadian healthcare companies. Investors will have the opportunity to obtain corporate updates from presenting companies, and participate in one-on-one meetings with company management.
http://markets.businessinsider.com/news/stocks/antibe-therapeutics-to-present-at-bloom-burton-co-healthcare-investor-conference-1022881006
Me neither!
Can we all go on Twitter and show them that shareholders don’t want no damn RS. Please vote if you have an twitter account. Thank you all
Will you be voting YES or NO to $AYTU proposal for the RS @AytuBioscience
— George (@George323818) April 28, 2018
Wonderful update. Can’t wait for next phase update with partnership, we going up guys. I’m betting the partnership is with the Nasdaq company and that is why they really want to be listed on Nasdaq.
ABcann Global Stands Out With Its Cannabis Cultivation Technologies
Sean Mason, SmallCapPower.com | Apr 22, 2018 01:42AM ET
h3 ABcann Global Corp (V:ABCN) estimates its revenues to grow multifold through 2021, reaching $500 million from less than $1.0 million run rate/h3
ABcann Global Corporation is a junior cannabis player holding a niche in cultivation technologies that deliver higher yields and consistent quality. ABcann is planning aggressive expansion of its flagship facility in Napanee, Ontario, with production targets of over 30,000 kgs annually by 2019.
https://www.investing.com/analysis/abcann-global-stands-out-with-its-cannabis-cultivation-technologies-200307587
ABcann Global Stands Out With Its Cannabis Cultivation Technologies
Sean Mason, SmallCapPower.com | Apr 22, 2018 01:42AM ET
h3 ABcann Global Corp (V:ABCN) estimates its revenues to grow multifold through 2021, reaching $500 million from less than $1.0 million run rate/h3
ABcann Global Corporation is a junior cannabis player holding a niche in cultivation technologies that deliver higher yields and consistent quality. ABcann is planning aggressive expansion of its flagship facility in Napanee, Ontario, with production targets of over 30,000 kgs annually by 2019.
https://www.investing.com/analysis/abcann-global-stands-out-with-its-cannabis-cultivation-technologies-200307587
ABcann Global Stands Out With Its Cannabis Cultivation Technologies
Sean Mason, SmallCapPower.com | Apr 22, 2018 01:42AM ET
h3 ABcann Global Corp (V:ABCN) estimates its revenues to grow multifold through 2021, reaching $500 million from less than $1.0 million run rate/h3
ABcann Global Corporation is a junior cannabis player holding a niche in cultivation technologies that deliver higher yields and consistent quality. ABcann is planning aggressive expansion of its flagship facility in Napanee, Ontario, with production targets of over 30,000 kgs annually by 2019.
https://www.investing.com/analysis/abcann-global-stands-out-with-its-cannabis-cultivation-technologies-200307587
Should be very interesting for sure. I’m not in this stock but thought I’d share with you guys bro. I do like the company a lot.
Thought I’d share this here since ABCann has a partnership deal with Syqe Medical
https://www.reuters.com/article/pmi-israel/philip-morris-to-invest-20-mln-in-firm-developing-inhaler-report-idUSL8N153292
Thought I’d share this here since ABCann has a partnership deal with Syqe Medical
https://www.reuters.com/article/pmi-israel/philip-morris-to-invest-20-mln-in-firm-developing-inhaler-report-idUSL8N153292
Emerald’s Executive Chairman, Avtar Dhillon, MD, will be interviewed today on Charles Payne’s Money Show running from 6 – 7 pm ET on Fox Business News.
Is there a US ticker?